In fi­nal re­port, ICER ap­pears to have a change of heart on new acute mi­graine ther­a­pies

ICER ap­pears to have re­versed course on its as­sess­ment of two acute mi­graine ther­a­pies.

The cost-ef­fec­tive­ness watch­dog in No­vem­ber is­sued a draft re­port sug­gest­ing that ex­ist­ing gener­ic med­i­cines are more ef­fec­tive and cheap­er than Al­ler­gan’s De­cem­ber-ap­proved CGRP ubro­gepant, Bio­haven ri­val mol­e­cule, rimegepant (which is un­der FDA re­view), and Lil­ly’s Oc­to­ber-sanc­tioned las­mid­i­tan, which binds to 5-HT1F re­cep­tors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.